G6PD deficiency affects females far more often than many people realize, but the way it shows up is fundamentally different from the classic pattern seen in males. Because the G6PD gene sits on the X chromosome, males who inherit a deficient copy have no backup and are fully affected. Females, with two X chromosomes, can carry one normal and one deficient copy, producing a mosaic of normal and deficient red blood cells whose proportions vary from woman to woman. This mosaic biology means that symptoms in heterozygous females range from nonexistent to severe, and standard screening tests routinely miss them.
Why Females Get G6PD Deficiency at All
G6PD deficiency is often described as a condition that “mainly affects males,” and while males are more frequently diagnosed, the genetics are more nuanced than that framing suggests. The G6PD gene sits on the X chromosome. Males carry one X, so a single deficient copy leaves every red blood cell short on the enzyme. Females carry two X chromosomes, which creates three possible scenarios: both copies normal, one normal and one deficient (heterozygous), or both copies deficient (homozygous).
Homozygous females are relatively uncommon, but when they do appear, their enzyme activity is comparable to that of deficient males. A large study in the Han Chinese population found no significant difference in G6PD activity between homozygous females and hemizygous males, with both groups averaging around 1 IU/g hemoglobin or less.1Scientific Reports. Glucose-6-phosphate dehydrogenase deficiency in the Han Chinese population: molecular characterization and genotype–phenotype association throughout an activity distribution Heterozygous females are far more numerous and present the real diagnostic puzzle, because their enzyme levels span a wide range depending on which X chromosome was silenced in which cells.
The Mosaic Effect and Why It Varies So Much
Early in embryonic development, each cell in a female randomly shuts down one of its two X chromosomes, a process called X-chromosome inactivation. Once a cell makes that choice, all its descendants keep the same X active. The result is that a heterozygous female ends up with two distinct populations of red blood cells: some producing normal G6PD and others producing the deficient version. The proportion is often close to a 50/50 split, but it can skew dramatically in either direction. Flow cytometric studies have documented that heterozygous females can have anywhere from about 1% to 85% normal red blood cells, with an average near 50%.2Wiley Open Access Collection. Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression
That range explains why two women carrying the exact same G6PD mutation can have completely different experiences. One might never know she has the trait; another might land in the hospital after eating fava beans. Research has found that the skewing is not purely random luck. A study of heterozygous women with G6PD Canton and Kaiping mutations found that preferential inactivation of the normal X chromosome occurred in about 86% of women who tested as enzyme-deficient, compared with roughly 32% of heterozygotes who tested normal.3Blood Cells, Molecules, and Diseases. DNA hypermethylation and X chromosome inactivation are major determinants of phenotypic variation in women heterozygous for G6PD mutations DNA methylation patterns in the G6PD promoter region appear to influence which X stays active, adding a layer of epigenetic control on top of the random inactivation.
Symptoms in Females
The symptoms of G6PD deficiency in females mirror those in males: hemolytic anemia triggered by oxidative stress, sometimes mild and self-limiting, sometimes severe enough to require transfusion. The difference is in frequency and predictability. A heterozygous female with mostly normal red blood cells may never experience a hemolytic episode. One with a large proportion of deficient cells can have reactions just as dangerous as those seen in fully deficient males.
The most recognizable triggers include fava beans, certain medications, and infections. Fava beans contain compounds called vicine and convicine that generate free radicals in red blood cells. In cells lacking adequate G6PD, the protective molecule glutathione cannot be recycled, and the oxidative damage destroys the cells.4Biomedical Research and Therapy. Severe Hemolysis Triggered by Favism in a Female Patient with G6PD Deficiency: A Case Report Favism is often assumed to be a male problem, but a study of 51 girls hospitalized for severe hemolytic crises after fava bean ingestion found that 61% were heterozygous and 39% were homozygous, demonstrating that heterozygous females can absolutely develop severe reactions.5Pediatric Research. Favism in GdMediterranean Heterozygous Females A case report also documented a 74-year-old woman who developed both hemolytic anemia and methemoglobinemia after eating raw fava beans.6PubMed Central. Co-occurrence of acute hemolytic anemia and methemoglobinemia in a 74-year-old female with G6PD deficiency: A case report
Henna application is another trigger that catches people off guard, particularly in communities where henna is used for celebrations. A case from Ghana documented severe intravascular hemolysis in a G6PD-deficient girl whose symptoms began three days after henna was applied to her skin for a Ramadan celebration.7PubMed Central. Henna-Induced Intravascular Hemolysis in a Glucose-6-Phosphate Dehydrogenase-Deficient Ghanaian Female Child with Full Defect The oxidative compound in henna, lawsone, can penetrate the skin and reach the bloodstream, posing a risk that many families and even clinicians are unaware of.
Drug-Induced Hemolysis and Antimalarials
The drug safety question is where G6PD deficiency in females has the most urgent clinical consequences. Primaquine and tafenoquine, used to clear dormant liver-stage malaria parasites, are known to cause hemolysis in G6PD-deficient individuals. What is less appreciated is the dose-dependent risk these drugs carry for heterozygous females. A study treating heterozygous women with primaquine for vivax malaria found clear dose-dependent hemolysis: at the standard dose, 82% of heterozygous women experienced substantial blood loss (more than 15% drop in hematocrit), compared with 38% at a half dose.8PLOS Medicine. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens
Tafenoquine, a newer single-dose alternative, carries similar risks. A dose-escalation study in healthy female volunteers heterozygous for the Mahidol variant showed that hemoglobin declines at 300 mg of tafenoquine were comparable to those seen with a full 14-day course of primaquine, and hemolysis was more pronounced in women with lower baseline G6PD enzyme activity.9PubMed Central. Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers Because tafenoquine has a long half-life and cannot be stopped mid-course like primaquine, the stakes of getting the diagnosis right beforehand are especially high. The prescribing requirement is strict: tafenoquine should only be given to patients with G6PD activity above 70% of the local population median, and quantitative testing rather than a simple qualitative screen is required for females.10PubMed Central. Tafenoquine and G6PD: a primer for clinicians
Modeling work has estimated that depending on the G6PD variant, only 8% to 19% of heterozygous females would test as deficient using a conservative 30% activity threshold, while 50% to 71% would be flagged at a 70% threshold.11PLoS Neglected Tropical Diseases. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria Where you draw the line determines how many women are protected from hemolysis and how many are unnecessarily denied treatment. A field study in Indonesia found that a 70% threshold correctly identified 92% of genotype-confirmed deficient females while only excluding about 1% of the normal female population from treatment.12PLoS Neglected Tropical Diseases. Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria
Neonatal Jaundice in Baby Girls
G6PD deficiency is a well-known cause of severe newborn jaundice, and here again the female picture is underappreciated. Deficient newborns are at risk of hyperbilirubinemia that can escalate to bilirubin-induced neurologic damage if untreated.13PubMed Central. Glucose-6-Phosphate Dehydrogenase Deficiency and Neonatal Hyperbilirubinemia: Insights on Pathophysiology, Diagnosis, and Gene Variants in Disease Heterogeneity While males make up the majority of deficient neonates, a large retrospective study of over 40,000 babies found that about 23% of G6PD-deficient newborns were female. The need for phototherapy did not differ significantly between sexes: roughly 26% of deficient males and 21% of deficient females required treatment.14Journal of Perinatology. Glucose-6-phosphate dehydrogenase deficiency and neonatal indirect hyperbilirubinemia: a retrospective cohort study among 40,305 consecutively born babies
Even heterozygous baby girls face elevated risk. A study comparing heterozygous, homozygous-deficient, and normal female neonates found that heterozygotes were roughly twice as likely to develop hyperbilirubinemia as normal girls, with third-day bilirubin levels averaging about 11.2 mg/dL versus 9.4 mg/dL in normal neonates.15Pediatrics. Neonatal Hyperbilirubinemia in Glucose-6-Phosphate Dehydrogenase-deficient Heterozygotes The practical takeaway is that newborn screening programs that only flag males with very low activity will miss a meaningful number of at-risk girls.
Why Standard Tests Miss Heterozygous Females
The most widely used screening tests for G6PD deficiency, like the fluorescent spot test, are designed to detect severely deficient individuals. They work well for hemizygous males and homozygous females, whose red blood cells are uniformly deficient. But a heterozygous female with, say, 55% normal red blood cells may produce enough total enzyme activity to pass the test, even though the other 45% of her red blood cells are completely defenseless against oxidative stress. A comparative study found that only about 14% of heterozygous carriers showed the severe enzyme deficiency that qualitative screening tests are calibrated to catch.16PubMed Central. Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency
This gap is not small. In one study using a ratio-based enzyme assay as the initial screen and then confirming with genetic testing, the enzyme assay missed about a third of female carriers who were confirmed to have G6PD mutations by molecular analysis.17PubMed Central. Reduction of Missed Diagnosis of G6PD Deficiency in Heterozygous Females by G6PD/6PGD Ratio Assay Combined with Amplification Refractory Mutation System PCR A woman told she has “normal” G6PD based on a standard screen might still carry a deficient variant and remain at risk for drug-induced hemolysis or other oxidative triggers.
Better Diagnostic Approaches
Flow cytometry is increasingly recognized as a more reliable way to diagnose G6PD deficiency in females. Unlike spectrophotometric tests that measure the average enzyme activity across all red blood cells, flow cytometry examines cells individually and can distinguish two separate populations: bright cells (normal G6PD) and dim cells (deficient). This cell-by-cell approach directly reveals the mosaic pattern unique to heterozygous females.
A systematic review and meta-analysis of flow cytometry’s diagnostic accuracy found pooled sensitivity of about 93% and specificity above 97% when compared against genetic testing or spectrophotometry.18Revista Ibero-Americana de Humanidades, Ciências e Educação. Flow Cytometry for the Diagnosis of Glucose-6-Phosphate Dehydrogenase Deficiency: A Systematic Review and Meta-Analysis In a Thai population study, flow cytometry was able to classify females into homozygous normal, heterozygous, and homozygous deficient categories with high accuracy, though it could not always distinguish between heterozygous females with extreme skewing and truly homozygous-deficient females.19PubMed Central. Cut-off values for diagnosis of G6PD deficiency by flow cytometry in Thai population A clinical implementation study over one year confirmed that flow cytometry detected cases of G6PD deficiency that standard spectrophotometry had missed, especially among heterozygous females with normal or near-normal total enzyme levels.20PubMed. Glucose-6-phosphate dehydrogenase deficiency detection using fluorocytometric assay: Evaluation after 1 year of clinical implementation
Genetic testing provides a definitive answer about whether a woman carries a G6PD mutation, but it comes with its own limitation: knowing the genotype does not tell you the phenotype. Because X-chromosome inactivation can shift the proportion of deficient red blood cells, and because that proportion may change over a woman’s lifetime, a genotype result alone cannot predict how much enzyme activity she has at any given moment. For this reason, clinical guidelines for heterozygous females often recommend both genetic confirmation and quantitative enzyme activity testing before prescribing drugs like tafenoquine.21PubMed Central. Incorporating G6PD genotyping to identify patients with G6PD deficiency
Pregnancy Considerations
Pregnancy adds a layer of complexity for women carrying G6PD variants. A study examining associations between G6PD gene variants and pregnancy outcomes found a strong link with preterm birth, with carriers of G6PD variants facing substantially higher odds of delivering early. Cholestasis and low blood cell counts in those women were additional independent risk factors for prematurity.22PubMed Central. Association between G6PD gene variants and adverse pregnancy outcomes The same study did not find an increased risk of miscarriage from G6PD variants alone, though gestational diabetes appeared to amplify that risk in carriers.
Medication safety during pregnancy is also a concern. Tafenoquine is contraindicated in pregnancy entirely, not only because of the mother’s potential deficiency but because the fetus could be G6PD-deficient regardless of the mother’s status, and the drug could harm fetal red blood cells. For the same reason, breastfeeding mothers are advised against tafenoquine unless the infant’s G6PD status is confirmed as normal.23PubMed Central. Tafenoquine Therapy and G6PD Genotype These restrictions highlight the importance of knowing your G6PD status before pregnancy or early in prenatal care, particularly if you live in or travel to malaria-endemic regions.
The Malaria Connection
G6PD deficiency persists at high frequencies in certain populations because it confers a survival advantage against malaria, a classic example of balancing selection. The relationship between sex, G6PD status, and malaria protection is not straightforward, though. Research in sub-Saharan Africa found that hemizygous males with the G6PD A− variant were protected against severe malaria, but heterozygous females with the same variant were not.24PLoS Medicine. X-Linked G6PD Deficiency Protects Hemizygous Males but Not Heterozygous Females against Severe Malaria The mosaic pattern in heterozygous females appears to dilute the protective effect: because a substantial fraction of their red blood cells produce normal G6PD, the parasite can still thrive in those cells.
An older study suggested the opposite, that heterozygous females might actually have greater resistance to malaria than males.25PubMed. Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant The discrepancy between these findings likely reflects differences in study design, malaria species, G6PD variants, and how protection was measured. What is clear is that heterozygous females occupy a biologically distinct position in the malaria-G6PD relationship, neither fully protected nor fully vulnerable, which mirrors their intermediate clinical profile more broadly.
How G6PD Research Shaped Our Understanding of X-Chromosome Biology
G6PD deficiency holds a special place in genetics history. The enzyme was one of the first tools scientists used to prove that random X-chromosome inactivation happens in human females. By studying women who carried two different forms of G6PD (type A and type B, each on a different X chromosome), researchers could show that individual cells expressed only one version, confirming that one X was being silenced at random in each cell.26PubMed Central. A history of the discovery of random x chromosome inactivation in the human female and its significance That same principle was then used to demonstrate that tumors like uterine fibroids grow from a single cell, since all cells in a given tumor expressed the same G6PD isoenzyme. The science of G6PD in females, in other words, did not just explain a blood disorder. It helped establish one of the foundational concepts in mammalian genetics.